Novartis biosimilar cancer drug hits U.S. regulatory bump
ZURICH (Reuters) - Novartis AG said its biosimilar version of rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis had not won regulatory approval from the U.S. Food and Drug Administration (FDA).
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Allergy & Immunology | Arthritis | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health | Rheumatoid Arthritis | Rheumatology | Rituxan